Interprotein Corporation is a Japanese brand that specializes in revolutionizing drug discovery. They offer a range of products and services aimed at analyzing and exploiting protein-protein interaction (PPI) interfaces to design and create PPI modulators. With their twin platform technologies, Interprotein provides highly active modulators for PPI targets.

Their proprietary technology, INTENDD ®, is a structure-based drug discovery strategy that generates highly active compounds with unique scaffolds. Additionally, their libraries of helix-loop-helix peptides have achieved a near 100% success rate in identifying strong binders with low nanomolar K D values, making them an excellent option for screening. Through collaborative research and development efforts, Interprotein aims to fully exploit their twin technologies to identify highly active modulators against previously intractable PPI interfaces.

They are committed to turning current biologics-based PPI inhibitions into more patient-friendly therapies with small molecule and/or peptide PPI modulators, ultimately changing patients' lives. Discover the cutting-edge advancements in drug discovery with Interprotein Corporation and experience the future of healthcare